The goal of acute treatment of an hereditary angioedema (HAE) attack is to reduce its duration and severity and thus limit its impact on the patient’s functional ability and prevent a potentially ...

Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that dat ...

Please provide your email address to receive an email when new articles are posted on . Respondents saw an average of nine patients with hereditary angioedema (HAE) each year. 82% of respondents said ...

From scant data, the armamentarium is expanding, with an increasing evidence base ...

Hereditary angioedema (HAE) is a serious, potentially fatal disease of recurrent swelling of various subcutaneous and submucosal tissues throughout the body. Swelling is mediated by uncontrolled ...

BioCryst Pharmaceuticals, Inc. announced promising new data regarding their oral prophylactic treatment, ORLADEYO (berotralstat), for hereditary angioedema (HAE) during the 14th C1-Inhibitor ...

Using CRISPR/Cas9 technology, the investigational therapy is designed to edit disease-causing genes inside the human body. The Food and Drug Administration (FDA) has granted Orphan Drug designation to ...

Deucrictibant significantly improved the time to onset of symptom relief, defined as PGI-C of at least “a little better”, compared with placebo (1.28 vs >12 hours). Topline data were announced from a ...

A new study shows a treatment using the CRISPR genome editing technology succeeded in alleviating swelling and reducing the frequency of attacks for those with hereditary angioedema. Hereditary ...

Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

Hereditary angioedema (HAE) is a rare genetic disorder involving a mutation in the C1 esterase inhibitor gene. This causes unpredictable attacks of severe swelling in your arms, legs, hands, feet, ...

Its not always possible to know when a hereditary angioedema (HAE) attack will strike. But specific triggers account for ...